Lanier Biotherapeutics
Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and ImmunoOncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL-25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
2
organic / mo
Sign up free to see all 2 verified contacts at Lanier Biotherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
- DW
Daniel White
Co-founder, President and CEO · General Business & Management
EmailPhone - CJ
Crystal Jackson
Director of Biological Sciences and Data Management · Other
EmailPhone
Showing 2 of 2 verified contacts
Top roles at Lanier Biotherapeutics
2 distinct titles indexed · top 2 shown.
- 1co-founder, president and ceo
- 1director of biological sciences and data management
Sign up to unlock all 2 contacts at Lanier Biotherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Lanier Biotherapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.